The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial

Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud Van Stiphout, Mary Kudsy, Josephine Morris, Valentina Ferrari, In Hwa Um, James Chettle, Farasat Kazmi, Leticia Campo, Alistair Easton, Sebastian Nijman, Michaela Serpi, Stefan Symeonides, Ruth Plummer, David J. Harrison, Gareth Bond, Sarah P. Blagden

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)clincanres.1652.2021
JournalClinical Cancer Research
Publication statusPublished - 8 Sep 2021

Cite this